Tykerb Tablet (Lapatinib 250mg) – HER2-Positive Breast Cancer Targeted Therapy

Tykerb (Lapatinib) is a prescription targeted oncology medication for the treatment of HER2-positive breast cancer (in combination with capecitabine or letrozole). As a targeted therapy, it works at a molecular level to slow cancer cell proliferation while sparing healthy tissue.
Composition: Lapatinib (250mg)
Manufacturer: Glaxo SmithKline Pharmaceuticals Ltd
Prescription-only oncology medication. Use only under the direct supervision of a licensed oncologist. Regular blood tests and monitoring are mandatory throughout treatment.